Catholic hospitals and pharmacies that are operating near or below break even in their provision of chemotherapy services are under increasing financial pressure following changes to the price paid under the Pharmaceutical Benefits Scheme (PBS) to supply chemotherapy drugs and another impending reduction, Catholic Health Australia has told a Senate Inquiry. The price reductions occur under a policy of "price disclosure" whereby the PBS price is brought into line with the market price once a drug comes off patent. CHA supports price disclosure, but has argued that hospital pharmacies need to be adequately paid for the professional work involved in preparing and supplying chemotherapy drugs.
Click here to read the submission.







